Loading clinical trials...

RECRUITINGNA

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

The Artificial Liver Support System (ALSS) in Patients With Acute on Chronic Liver Failure - the Use of Combined Molecular Adsorption System With Double Plasma (DPMAS) and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation and the Function of Vital Organs.

NCT07329036•Institute for Clinical and Experimental Medicine

View on ClinicalTrials.gov

Summary

The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.

Detailed Description

In patients with ACLF we assume the use of the proposed protocol of combined support therapy (consisting of a hemoadsorption system - DPMAS (double plasma molecular absorption system) and therapeutic plasma (TPE), with the basic aim of improving clinical condition (organ dysfunction) to allow the regeneration of liver parenchyma or to perform liver transplantation.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patient, age ≥18 years
•Expressed consent to the inclusion
•Patient hospitalized on ICU with ALF or ACLF diagnosis
•Recently meeting the inclusion to liver transplantation
•Present on a waiting list to liver transplant
•Unsuitable for inclusion to liver transplantation - indicated for support therapy only, but not indented to palliative care

Exclusion Criteria

•Disagreement with the study
•Infaust prognosis with expected survival less than 24 hours
•Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.
•Advanced oncological disease (expected life expectancy below 6 months)
•Severe degree of Frailty syndrome in secondary severe sarcopenia (muscle and malnutrition) or reduced performance state according

Locations (1)

Institute for Clinical and Experimental Medicine (IKEM)

Prague, Czechia

Key Dates

Start Date

April 1, 2024

Primary Completion Date

December 1, 2026

Completion Date

December 31, 2026

Last Updated

January 9, 2026

Enrollment

ESTIMATED participants

Conditions

Acute Liver Failure

Interventions

The artificial liver support system (ALSS) - DPMAS/TPE

DEVICE

Contacts

Petr Piza, MD, MHA

CONTACT

+420 602 225 077 petr.piza@ikem.cz

Eva Kieslichova, ass. prof., MD, PhD

CONTACT

+420 261 363 350 evki@ikem.cz

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

NCT06831643

Acute Liver Failure

View study

ACTIVE_NOT_RECRUITINGNA

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

NCT06872372

Acute Liver FailureDrug-Induced Liver Injury

View study

NOT_YET_RECRUITINGEARLY_PHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF

Inclusion Criteria

Exclusion Criteria

Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure

Safety and Tolerability of Hepatocyte-like Cell Therapy for Liver Failure and Small-for-Size Syndrome

Longitudinal Study of Mitochondrial Hepatopathies

Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct

One Way to Diagnose Hepatic Insufficiency the First Postoperative Day After Resection: Prospective Cohort Study